Next, we investigated the effects of combining IMGN853 with antiangiogenic agents by evaluating the efficacy of treating mice bearing the orthotopic OVCAR-8 ip2-luc model with IMGN853 and the anti–human/mouse VEGF-A antibody B20, both individually and in combination (Fig. 7A), following tumor establishment confirmed through BLI (Fig. 7B). The gene discussed is VEGFA; the disease is neoplasm.